Clinical Trials
40 trialsNCT04633122 2026-04-03
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
NCT03673501 2026-02-05
INTRIGUE
Deciphera Pharmaceuticals, LLC
Phase 3 Active not recruiting
NCT00756509 2026-01-20
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
Novartis
Phase 4 Completed
NCT04282980 2025-03-03
A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
NCT02401815 2025-02-14
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
Cogent Biosciences, Inc.
Phase 1/2 Completed
NCT04825574 2024-11-26
Study for Patients Previously Treated in Avapritinib Clinical Trials
Blueprint Medicines Corporation
Phase 4 Completed
NCT03345485 2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2 Completed
NCT01863745 2024-08-19
Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
Novartis
Phase 2 Completed
NCT05160168 2024-06-05
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Theseus Pharmaceuticals
Phase 1/2 Terminated
NCT04276415 2024-02-15
DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)
Daiichi Sankyo
Phase 1 Terminated
NCT01735955 2024-02-08
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Novartis
Phase 4 Completed
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT00716820 2023-04-06
Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
Pfizer
Completed
NCT03353753 2022-11-21
INVICTUS
Deciphera Pharmaceuticals, LLC
Phase 3 Completed
NCT03465722 2022-10-06
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Blueprint Medicines Corporation
Phase 3 Completed
NCT02508532 2022-06-21
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Blueprint Medicines Corporation
Phase 1 Completed
NCT01275222 2021-06-25
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
Novartis
Phase 1/2 Completed
NCT01271712 2021-01-29
GRID
Bayer
Phase 3 Completed
NCT02452424 2020-03-05
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Daiichi Sankyo
Phase 1/2 Terminated
NCT00428220 2019-06-27
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Pfizer
Phase NA Completed
NCT01396148 2019-03-27
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Pfizer
Phase 2 Completed
NCT01874665 2018-05-18
GIST
Takeda
Phase 2 Completed
NCT00867113 2018-03-14
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
Novartis
Phase 2 Completed
NCT01831726 2017-03-20
SIGNATURE
Novartis
Phase 2 Completed
NCT01316263 2017-03-09
A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors
Eli Lilly and Company
Phase 2 Terminated
NCT00444795 2017-02-01
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
Pfizer
Completed
NCT01289028 2017-01-02
Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
Novartis
Phase 3 Completed
NCT00785785 2016-06-16
ENESTg1
Novartis
Phase 3 Completed
NCT01478373 2016-04-27
Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
Novartis
Phase 2 Completed
NCT01039519 2016-03-10
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
Synta Pharmaceuticals Corp.
Phase 2 Completed
NCT00793871 2015-11-20
GIST
Pfizer
Phase 4 Completed
NCT00237185 2014-08-19
A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene
Novartis
Phase 2 Completed
NCT00751036 2014-03-26
MACS0375
Novartis
Phase 3 Terminated
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00385203 2012-07-16
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
AstraZeneca
Phase 2 Completed
NCT00471328 2012-06-12
ENEST
Novartis
Phase 3 Completed
NCT00372567 2011-03-17
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
Pfizer
Phase 3 Terminated
NCT00457743 2009-11-13
A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)
Pfizer
Phase 1/2 Completed
NCT00075218 2009-09-28
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
Pfizer
Phase 3 Completed
NCT00137449 2009-09-15
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
Pfizer
Phase 2 Completed